Sermo, the world’s largest online community for physicians, announced a free Sermo Report titled, “FDA Committee Recommends Approval for Ticagrelor.” The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome (ACS). According to the results, 46% of physicians feel that ticagrelor will likely affect the current standard of care, Plavix (clopidogrel), for ACS patients. If approved, 57% of physicians said they could switch up to 20% of their patients to ticagrelor.
The Sermo Report polled 60 physicians, many of who also participated in a discussion about the treatment. Acute coronary syndrome (ACS) incorporates a number of symptoms consistent with the probability that a patient is suffering from active Myocardial Infarction. Competitors to ticagrelor include Bristol-Myers Squibb Co. and Sanofi-Aventis’, Plavix and Effient, sold by Eli Lilly & Company.
“Physicians on Sermo see ticagrelor as significantly impactful to clinicians,” said Adam Sharp, Chief Medical Officer at Sermo. “However, cost and time in market could slow adoption. While more research on physician awareness still needs to be done, it’s also interesting to note that 50% of docs did not know about the FDA approval before seeing it on Sermo.”
Source: Sermo